Trial Profile
Activity of Regorafenib in Combination With Modified Gemcitabine - Oxaliplatin Chemotherapy (mGEMOX) in Patients With Advanced Biliary Tract Cancer (BTC): A Phase Ib-II Trial (BREGO)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Nov 2021
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary) ; Gemcitabine; Oxaliplatin
- Indications Adenocarcinoma; Biliary cancer; Gallbladder cancer
- Focus Adverse reactions
- Acronyms BREGO
- 07 Jan 2020 Status changed from recruiting to completed.
- 05 Jun 2018 Results of phase 1b (n=20) assessing recommended phase II dose (RP2D) of regorafenib combined with mGEMOX as first-line therapy of aBTC, were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 20 Jan 2018 Results of phase Ib part of this study (n=22) presented at the 2018 Gastrointestinal Cancers Symposium.